Recent Updates
Recently added Catalysts

lactoserum

Phase 3

Hygiene | Small molecule | Other |Sanofi|Last Updated: May 16, 2008

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDBiomarker
Total Trials4
Total Enrollment160
FDA Designations
No designations recorded
Clinical Trials (4)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00397527Acceptability Dermacyd Wipes - Lactoserum - HygienePHASE3 COMPLETED 30Jul 1, 2006 -May 16, 20081 Brazil
NCT00370162Acceptability Dermacyd Delicata - New Fragrance - Lactoserum - HygienePHASE3 COMPLETED 30Jun 1, 2006 -May 16, 20081 Brazil
NCT00371852Topic Compatibility Dermacyd Wipes - Lactoserum - HygienePHASE3 COMPLETED 50May 1, 2006 -May 16, 20081 Brazil
NCT00380991Topic Compatibility Dermacyd Delicata - New Fragrance - Lactoserum - HygienePHASE3 COMPLETED 50May 1, 2006 -May 16, 20081 Brazil
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Adverse events and their association with the treatment.
Adverse Events and its association with the drug in study
Score evaluation of the cutaneous reaction, preconized by International Contact Dermatitis Research Group (ICDRG)
Unlock Study Endpoints
Study Design & Arms
AllocationNON_RANDOMIZED
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Interventions
NameTypeDescription
lactoserumDRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 60 Years
SexFEMALE
Healthy VolunteersYes
Study Sites1

The following information on clinical trials is provided for information purposes only to allow patients and physicians to have an initial discussion about the trial. This information is not intended to be complete information about the trial, to contain all considerations that may be relevant to po...

Countries:Brazil
Unlock Eligibility Criteria